{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:47:45Z","timestamp":1791906465410,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trecan.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:05:47Z","timestamp":1784088347000},"page":"962-981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant immunotherapy in breast cancer: Progress and challenges"],"prefix":"10.1016","volume":"12","author":[{"given":"Manon","family":"de Graaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"De Caluw\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Buisseret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.06.009_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.breast.2021.02.009","article-title":"Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis","volume":"57","author":"Salvo","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.trecan.2026.06.009_bb0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ijc.31914","article-title":"Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study","volume":"144","author":"van Maaren","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2026.06.009_bb0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13058-024-01881-y","article-title":"Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis","volume":"26","author":"Morgan","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0025","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0035","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","article-title":"Pathological complete response in neoadjuvant treatment of breast cancer","volume":"22","author":"Cortazar","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2026.06.009_bb0050","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0055","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0060","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0065","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jama.2024.26886","article-title":"Adjuvant atezolizumab for early triple-negative breast cancer: the ALEXANDRA\/IMpassion030 randomized clinical trial","volume":"333","author":"Ignatiadis","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2026.06.009_bb0070","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.025","article-title":"LBA15 \u2013 low dose pembrolizumab in addition to neoadjuvant anthracycline and taxane in triple-negative breast cancer: a randomized controlled trial","volume":"36","author":"Batra","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0080","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.06.009_bb0085","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-GS3-05","volume":"31","author":"Geyer","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0090","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0095","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0100","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO-25-02311","article-title":"Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer: long-term analysis from the GeparNuevo trial","volume":"44","author":"Loibl","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0105","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0110","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0115","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41523-024-00676-w","article-title":"Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer","volume":"10","author":"Bonadio","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2026.06.009_bb0135","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.06.009_bb0140","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1509820","article-title":"Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival","volume":"7","author":"Sobral-Leite","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.06.009_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41523-023-00543-0","article-title":"Immune landscape of breast tumors with low and intermediate estrogen receptor expression","volume":"9","author":"Voorwerk","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2026.06.009_bb0150","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s43018-023-00542-x","article-title":"PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial","volume":"4","author":"Voorwerk","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.06.009_bb0160","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2026.06.009_bb0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.annonc.2024.10.018","article-title":"Pathologic complete response (pCR) rates for patients with HR+\/HER2\u2212 high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial","volume":"36","author":"Huppert","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0170","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1078-0432.CCR-21-2260","article-title":"Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: results of the phase II GIADA trial","volume":"28","author":"Dieci","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0180","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105907","article-title":"PROMENADE: pembrolizumab for early ER-low\/HER2-negative breast cancer, real-world French cohort","volume":"10","author":"Cherifi","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.trecan.2026.06.009_bb0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0200","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0205","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0210","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.06.009_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0220","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III IMpassion050 trial","volume":"40","author":"Huober","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0225","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-LBO1-02","article-title":"Abstract LBO1-02: pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial","volume":"84","author":"Gianni","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0230","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s43018-024-00890-2","article-title":"Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52\/ATHENE trial","volume":"6","author":"Rinnerthaler","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.06.009_bb0235","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jamaoncol.2022.2310","article-title":"Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage II\/III breast cancer: the Neo-PATH phase 2 nonrandomized clinical trial","volume":"8","author":"Ahn","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0240","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-RF3-05","article-title":"Abstract RF3-05: a phase 2 study of neoadjuvant HER2-targeted therapy +\/\u2212 immunotherapy with pembrolizumab (neoHIP)","volume":"31","author":"McArthur","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0245","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.2024.42.16_suppl.608","article-title":"Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702\u2014survival results","volume":"42","author":"Loi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0250","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2249","article-title":"LBA11 neoadjuvant nivolumab\/relatlimab or nivolumab\/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)","volume":"35","author":"Nederlof","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102240","article-title":"The promise of bispecific antibodies: clinical applications and challenges","volume":"99","author":"Lim","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trecan.2026.06.009_bb0270","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/1078-0432.CCR-20-3770","article-title":"Bispecific immunomodulatory antibodies for cancer immunotherapy","volume":"27","author":"Blanco","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0275","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2025.43.16_suppl.599","article-title":"Neoadjuvant cadonilimab (anti-PD-1\/CTLA-4 bispecific antibody) plus chemotherapy in early or locally advanced triple-negative breast cancer: a single-arm phase II trial (CABIN study)","volume":"43","author":"Wu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0280","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2026.06.009_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trecan.2026.06.009_bb0290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0295","doi-asserted-by":"crossref","first-page":"S1566","DOI":"10.1016\/j.annonc.2025.09.031","volume":"36","author":"Dent","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0300","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0305","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for combining immune checkpoint blockade with PARP inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0310","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11912-025-01669-z","article-title":"PARP inhibitors in the neoadjuvant setting; a comprehensive overview of the rationale for their use, past and ongoing clinical trials","volume":"27","author":"Habaka","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.trecan.2026.06.009_bb0315","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.06.009_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2023.103580","article-title":"Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative primary breast cancer: results from CheckMate 7A8","volume":"72","author":"Jerusalem","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.trecan.2026.06.009_bb0325","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO1-01-09","article-title":"Abstract PO1-01-09: neoadjuvant endocrine therapy and avelumab with or without palbociclib in stage II\/III endocrine receptor-positive breast cancer: the ImmunoADAPT trial","volume":"84","author":"Zavras","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0330","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","article-title":"Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0335","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1038\/s41591-025-03734-3","article-title":"Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial","volume":"31","author":"Gion","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.06.009_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110836","article-title":"Adapting radiation therapy to immunotherapy: delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial","volume":"206","author":"De Caluw\u00e9","year":"2025","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0350","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.06.009_bb0355","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04453-z","article-title":"Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+\/HER2\u2212 breast cancer: a randomised phase 2 trial","author":"De Caluw\u00e9","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0360","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.24.00003","article-title":"PEARL: a phase Ib\/II biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2-negative breast cancer","volume":"42","author":"Ho","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0365","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-GS2-05","article-title":"Abstract GS2-05: primary results from the HR+\/HER2\u2212 cohort of TBCRC-053 (P-RAD): a randomized trial of no, low, or high dose preoperative RADiation with pembrolizumab and chemotherapy in node-positive, HER2-negative breast cancer","volume":"32","author":"Gupta","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0370","series-title":"Pathological Complete Response in Neoadjuvant Treatment of High-risk Early-stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.trecan.2026.06.009_bb0375","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1200\/JCO-24-01360","article-title":"Surrogate end points for overall survival in neoadjuvant randomized clinical trials for early breast cancer","volume":"43","author":"Conforti","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0380","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.22.02363","volume":"41","author":"Squifflet","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0385","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-PS4-12-24","article-title":"Abstract PS4-12-24: risk and pattern of relapse in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: updated results from the European GAMBIT real-world study","volume":"32","author":"Dieci","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0390","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0395","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0400","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"379","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0405","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-LB1-07","article-title":"Abstract LB1-07: exploratory biomarker analysis of the phase 3 KEYNOTE-522 study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage TNBC","volume":"31","author":"O\u2019Shaughnessy","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0410","article-title":"Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer","volume":"5","author":"Rached","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0415","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-025-07758-8","article-title":"Adverse events in patients treated with neoadjuvant chemo\/immunotherapy for triple negative breast cancer: results from seven academic medical centers","volume":"213","author":"Mezzanotte-Sharpe","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2026.06.009_bb0420","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-GS5-03","article-title":"Abstract GS5-03: evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: results from the neoadjuvant I-SPY 2 TRIAL","volume":"83","author":"Isaacs","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0425","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0430","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(24)00757-5","article-title":"Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902\/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial","volume":"26","author":"Zdenkowski","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0435","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1285","article-title":"Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: an indirect meta-analysis","volume":"7","author":"Zhou","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.trecan.2026.06.009_bb0440","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1158\/1078-0432.CCR-24-0149","article-title":"The immune-related 27-gene signature DetermaIO predicts response to neoadjuvant atezolizumab plus chemotherapy in triple-negative breast cancer","volume":"30","author":"Dugo","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.06.009_bb0445","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2022.40.16_suppl.514","article-title":"The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2","volume":"40","author":"Mittempergher","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0450","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.06.009_bb0455","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/cells12121573","article-title":"Circulating tumor DNA in the management of early-stage breast cancer","volume":"12","author":"Vlataki","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.trecan.2026.06.009_bb0460","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s41591-025-03725-4","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"31","author":"Mittendorf","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.06.009_bb0465","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(25)00097-X","article-title":"Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial","volume":"26","author":"Kuemmel","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0470","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1200\/JCO-25-02934","article-title":"The pathologic response evaluation and detection in circulating tumor-DNA study: ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease","volume":"44","author":"Hunter","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.06.009_bb0475","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.annonc.2025.03.019","article-title":"Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"36","author":"Valenza","year":"2025","journal-title":"Ann. Oncol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:12:15Z","timestamp":1791904335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326001378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":95,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405803326001378"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.06.009","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant immunotherapy in breast cancer: Progress and challenges","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}